Cell
AssigneeUCL Business PLC
InventorsMartin Pulé, Khai Kong, Shaun Cordoba
Life of this patent
Estimating the term…
Abstract
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.
Claims16
A T cell or natural killer (NK) cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising:
- (i) an antigen-binding domain;
- (ii) a spacer
- (iii) a trans-membrane domain;
- and
- (iv) an endodomain
- wherein the antigen binding domains of the first and second CARs bind to different antigens,
- wherein the spacer of the first CAR is different from the spacer of the second CAR such that when both first and second CARs bind their target antigen, the difference in spacer dimensions results in spatial separation of the activating and inhibitory CARs to different parts of the membrane,
- wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain, and
- wherein the ligation-off inhibitory endodomain comprises a CD148 or CD45 tyrosine phosphatase domain.
Dependencies are inferred from the claim text.